Literature DB >> 9241125

Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.

J C Tardif1, G Cöté, J Lespérance, M Bourassa, J Lambert, S Doucet, L Bilodeau, S Nattel, P de Guise.   

Abstract

BACKGROUND: Oxidizing metabolites generated at the site of coronary angioplasty can induce chain reactions that may lead to restenosis. Antioxidants may counter oxidative stress and modify neointimal formation and vascular remodeling. Experimental data and small clinical studies have suggested that antioxidants may prevent restenosis after angioplasty. In a double-blind, randomized trial, we studied whether drugs with antioxidant properties decrease the incidence and severity of restenosis after angioplasty.
METHODS: One month before angioplasty, 317 patients were randomly assigned to receive one of four treatments: placebo, probucol (500 mg), multivitamins (30,000 IU of beta carotene, 500 mg of vitamin C, and 700 IU of vitamin E), or both probucol and multivitamins-all given twice daily. Patients were treated for four weeks before and six months after angioplasty. Patients received an extra 1000 mg of probucol, 2000 IU of vitamin E, both probucol and vitamin E, or placebo 12 hours before angioplasty, according to their treatment assignments. Base-line and follow-up angiograms were interpreted by blinded investigators using a quantitative approach.
RESULTS: The mean (+/-SD) reduction in luminal diameter six months after angioplasty was 0.12 +/- 0.41 mm in the probucol group, 0.22 +/- 0.46 mm in the combined-treatment group, 0.33 +/- 0.51 in the multivitamin group, and 0.38 +/- 0.50 mm in the placebo group (P = 0.006 for those receiving vs. those not receiving probucol, and P = 0.70 for those receiving vs. those not receiving vitamins. Restenosis rates per segment were 20.7 percent in the probucol group, 28.9 percent in the combined-treatment group, 40.3 percent in the multivitamin group, and 38.9 percent in the placebo group (P = 0.003 for probucol vs. no probucol). The rates of repeat angioplasty were 11.2 percent. 16.2 percent, 24.4 percent, and 26.6 percent, respectively (P = 0.009 for probucol vs. no probucol).
CONCLUSIONS: The antioxidant probucol is effective in reducing the rate of restenosis after balloon coronary angioplasty.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241125     DOI: 10.1056/NEJM199708073370601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  69 in total

1.  "Oxidative protector" enzymes in the macular retinal pigment epithelium of aging eyes and eyes with age-related macular degeneration.

Authors:  R N Frank
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 2.  What is meant by intention to treat analysis? Survey of published randomised controlled trials.

Authors:  S Hollis; F Campbell
Journal:  BMJ       Date:  1999-09-11

Review 3.  Randomised controlled trials in cardiovascular medicine: past achievements, future challenges.

Authors:  S Yusuf
Journal:  BMJ       Date:  1999-08-28

Review 4.  Treatment of atherosclerotic disease at the cervical carotid bifurcation: current status and review of the literature.

Authors:  J J Connors; D Seidenwurm; J C Wojak; R W Hurst; M E Jensen; R Wallace; T Tomsick; J Barr; C Kerber; E Russell; G M Nesbit; A J Fox; F Y Tsai
Journal:  AJNR Am J Neuroradiol       Date:  2000-03       Impact factor: 3.825

5.  Effective management of stable angina.

Authors:  M Petticrew; M Sculpher; J Kelland; R Elliott; D Holdright; M Buxton
Journal:  Qual Health Care       Date:  1998-06

6.  Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation.

Authors:  Yong-sheng Jiang; Jing-an Lei; Fang Feng; Qi-ming Liang; Fu-rong Wang
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

Review 7.  Targeting NADPH oxidases in vascular pharmacology.

Authors:  Agata Schramm; Paweł Matusik; Grzegorz Osmenda; Tomasz J Guzik
Journal:  Vascul Pharmacol       Date:  2012-03-03       Impact factor: 5.773

Review 8.  Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease.

Authors:  Paul G Shekelle; Sally C Morton; Lara K Jungvig; Jay Udani; Myles Spar; Wenli Tu; Marika J Suttorp; Ian Coulter; Sydne J Newberry; Mary Hardy
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

Review 9.  Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.

Authors:  Pramod Kuchulakanti; Ron Waksman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress.

Authors:  Edzard Schwedhelm; Renke Maas; Raphael Troost; Rainer H Böger
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.